Apogee Therapeutics Inc.

NASDAQ: APGE · Real-Time Price · USD
38.27
1.92 (5.28%)
At close: Aug 22, 2025, 3:59 PM
37.51
-1.99%
After-hours: Aug 22, 2025, 07:23 PM EDT

Apogee Therapeutics Statistics

Share Statistics

Apogee Therapeutics has 59.6M shares outstanding. The number of shares has increased by 1.79% in one year.

59.6M
1.79%
0.05%
99.99%
48.32M
2,190
0.25%

Short Selling Information

The latest short interest is 8.4M, so 14.4% of the outstanding shares have been sold short.

8.4M
14.4%
30.66%
12.37

Valuation Ratios

The PE ratio is -13.73 and the forward PE ratio is -6.5. Apogee Therapeutics's PEG ratio is -0.14.

-13.73
-6.5
0
n/a
3.49
-14.51
-0.14
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Apogee Therapeutics.

n/a
n/a
n/a
n/a

Financial Position

The company has a current ratio of 18.55, with a Debt / Equity ratio of 0.02.

18.55
18.55
0.02
-0.05
-0.07
0

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

n/a
n/a
n/a
n/a
$-929.32K
196
0
n/a

Taxes

-18K
0.01%

Stock Price Statistics

The stock price has increased by -23.99% in the last 52 weeks. The beta is 1.44, so Apogee Therapeutics's price volatility has been higher than the market average.

1.44
-23.99%
39.58
40.54
44
885,359

Income Statement

n/a
-189K
-216.87M
-182.15M
-216.87M
-182.13M
-3.3
Full Income Statement

Balance Sheet

The company has 141.79M in cash and 11.83M in debt, giving a net cash position of 129.96M.

141.79M
11.83M
129.96M
-305.92M
657.77M
484.57M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -171.17M and capital expenditures -1.15M, giving a free cash flow of -172.33M.

-171.17M
-1.15M
-172.33M
-3.12
Full Cash Flow Statement

Margins

n/a
n/a
n/a
n/a
n/a
n/a
n/a

Dividends & Yields

APGE does not appear to pay any dividends at this time.

n/a
n/a
n/a
n/a
n/a
n/a
Dividend Details

Analyst Forecast

The average price target for APGE is $92.5, which is 154.5% higher than the current price. The consensus rating is "Buy".

$92.5
154.5%
Buy
4
Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

n/a
n/a
n/a
n/a

Scores

30.87
1